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### Transcatheter Valve-in-Valve Aortic Valve Replacement as an Alternative to Surgical Re-Replacement![](fx1_lrg.gif) {#sec1.1.1}
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This study analyzed the outcomes of valve-in-valve (VIV) transcatheter aortic valve replacement (TAVR) versus redo surgical aortic valve replacement (SAVR) in a propensity-matched analysis at a nationwide level in France. At 30 days, VIV TAVR was associated with a lower rate of major clinical events (composite of all-cause mortality, all-cause stroke, myocardial infarction, major or life-threatening bleeding) (odds ratio \[OR\]: 0.62; 95% confidence interval \[CI\]: 0.44 to 0.88; p = 0.03). During follow-up, the combined endpoint of cardiovascular death, all-cause stroke, myocardial infarction, or rehospitalization for heart failure was not different between VIV TAVR and the redo SAVR group (OR: 1.18; 95% CI: 0.99 to 1.41; p = 0.26). Overall, outcomes of VIV TAVR were significantly improved since 2015.
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### Repeat Aortic Valve Surgery or Transcatheter Valve-in-Valve Therapy: We Need a Randomized Trial {#sec1.2.1}
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Michael A. Borger, Matthias Raschpichler, Raj Makkar
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### Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF![](fx1_lrg.gif) {#sec1.3.1}
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Jonathan W. Cunningham, Brian L. Claggett, Eileen O'Meara, Margaret F. Prescott, Marc A. Pfeffer, Sanjiv J. Shah, Margaret M. Redfield, Faiez Zannad, Lu-May Chiang, Adel R. Rizkala, Victor C. Shi, Martin P. Lefkowitz, Jean Rouleau, John J.V. McMurray, Scott D. Solomon, Michael R. Zile

This study hypothesized that biomarkers reflecting mechanisms of extracellular matrix (ECM) homeostasis would be abnormal in patients with heart failure with preserved ejection fraction (HFpEF) enrolled in the PARAGON-HF (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction) trial, predict clinical outcomes, and change in response to sacubitril/valsartan. Biomarkers reflecting ECM homeostasis are altered in HFpEF and sacubitril/valsartan significantly affected these biomarkers. Baseline and change in biomarkers reflecting ECM homeostasis have important prognostic value. These findings suggest that abnormal ECM homeostasis may contribute to HFpEF pathophysiology and prognosis and may be altered by sacubitril/valsartan.
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### Sacubitril/Valsartan as Antifibrotic Drug: Rejuvenating the Fibrosed HFpEF Heart {#sec1.4.1}
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### Cardiovascular and Bleeding Risks Associated With Nonsteroidal Anti-Inflammatory Drugs After Myocardial Infarction![](fx1_lrg.gif) {#sec1.5.1}
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Dong Oh Kang, Hyonggin An, Geun U Park, Yunjin Yum, Eun Jin Park, Yoonjee Park, Won Young Jang, Woohyeun Kim, Jah Yeon Choi, Seung-Young Roh, Jin Oh Na, Jin Won Kim, Eung Ju Kim, Seung-Woon Rha, Chang Gyu Park, Hong Seog Seo, Cheol Ung Choi

The authors investigated the impact of concomitant nonsteroidal anti-inflammatory drug (NSAID) treatment with antithrombotic therapy in patients with myocardial infarction (MI) by analyzing the Korean nationwide prescription claims database. Concomitant NSAID treatment significantly increased the risk for cardiovascular and bleeding events after MI in this nationwide population. Celecoxib and meloxicam showed a relatively safe profile among the various subtypes of NSAIDs by demonstrating the lowest risk for cardiovascular and bleeding events. Thus, although concomitant NSAID treatment should be avoided in patients with histories of MI, celecoxib and meloxicam could be considered as alternative options when NSAID use is unavoidable.
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### Is Increased Cardiovascular and Bleeding Risk the Price for Pain Relief? No Free Lunch {#sec1.6.1}
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### Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection![](fx1_lrg.gif)![](fx3_lrg.gif)![](fx4_lrg.gif) {#sec1.7.1}

[533](http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(20)35552-2){#intref0040}

Anuradha Lala, Kipp W. Johnson, James L. Januzzi, Adam J. Russak, Ishan Paranjpe, Felix Richter, Shan Zhao, Sulaiman Somani, Tielman Van Vleck, Akhil Vaid, Fayzan Chaudhry, Jessica K. De Freitas, Zahi A. Fayad, Sean P. Pinney, Matthew Levin, Alexander Charney, Emilia Bagiella, Jagat Narula, Benjamin S. Glicksberg, Girish Nadkarni, Donna M. Mancini, Valentin Fuster, on behalf of the Mount Sinai COVID Informatics Center

Myocardial injury reflected as elevated troponin in coronavirus disease-2019 (COVID-19) is not well characterized among U.S. patients. The authors describe the prevalence of myocardial injury and its impact on outcomes among hospitalized patients with confirmed COVID-19 who had troponin-I measurements within 24 h of admission (n = 2,736). Elevated troponin concentrations (normal \<0.03 ng/ml) were commonly observed in patients hospitalized with COVID-19, most often present at low levels, and associated with increased risk of death. Patients with cardiovascular disease (CVD) or CVD risk factors were more likely to have myocardial injury.
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### Myocardial Injury in COVID-19 Patients: The Beginning or the End? {#sec1.8.1}
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### Penetrance of Hypertrophic Cardiomyopathy in Sarcomere Protein Mutation Carriers![](fx1_lrg.gif) {#sec1.9.1}
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Massimiliano Lorenzini, Gabrielle Norrish, Ella Field, Juan Pablo Ochoa, Marcos Cicerchia, Mohammed M. Akhtar, Petros Syrris, Luis R. Lopes, Juan Pablo Kaski, Perry M. Elliott

This study investigated penetrance of hypertrophic cardiomyopathy (HCM) by analyzing 285 adult and pediatric sarcomere protein mutation carriers who did not fulfill diagnostic criteria for HCM at first evaluation. The estimated penetrance of HCM was higher than previously described, reaching approximately 50% at 15 years follow-up. Male sex and electrocardiogram abnormalities emerged as risk factors for a higher penetrance and may be useful to guide follow-up. Because a subgroup was diagnosed with cardiac magnetic resonance (CMR) but not echocardiography, the study supports the use of regular CMR in long-term screening.
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### Variable Penetrance in Hypertrophic Cardiomyopathy: In Search of the Holy Grail {#sec1.10.1}
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### Targeting RNA With Antisense Oligonucleotides and Small Interfering RNA in Dyslipidemias: *JACC* State-of-the-Art Review![](fx1_lrg.gif) {#sec2.1.1}

[563](http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(20)35562-5){#intref0060}

Julius L. Katzmann, Chris J. Packard, M. John Chapman, Isabell Katzmann, Ulrich Laufs

Despite contemporary treatments, residual cardiovascular risk attributable to low-density lipoprotein and remnant particles persists. Pharmacological targeting of messenger RNA with antisense oligonucleotides and small interfering RNA represents an emerging, innovative approach. These drugs can be directed specifically to the liver by conjugation with *N*-acetylgalactosamine. Inhibiting the translation of key regulatory proteins such as PCSK9, apolipoprotein CIII, apolipoprotein(a), and angiopoietin-like 3 favors normalization of dyslipidemia. These agents have several advantages, including very long dosing intervals and the potential to regulate the abundance of any disease-related protein. Cardiovascular outcome trials are ongoing to assess their effects on clinical outcomes and long-term safety.
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### Randomized Trials Versus Common Sense and Clinical Observation: *JACC* Review Topic of the Week![](fx1_lrg.gif) {#sec2.2.1}
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Alexander C. Fanaroff, Robert M. Califf, Robert A. Harrington, Christopher B. Granger, John J.V. McMurray, Manesh R. Patel, Deepak L. Bhatt, Stephan Windecker, Adrian F. Hernandez, C. Michael Gibson, John H. Alexander, Renato D. Lopes

Citing concerns about the generalizability of results from traditional randomized clinical trials (RCTs) and the growth of real-world data, some have argued that common sense and clinical observation, rather than RCTs, should be the preferred source of knowledge to support clinical decision-making. However, well-conducted RCTs have repeatedly contradicted practices supported by common sense and clinical observation. With hindsight, it is clear that common sense and clinical observation fail because of the impossibility of comprehensively understanding how treatments will affect biopsychosocial systems. Concerns about RCT models are legitimate, but randomization, ideally built into real-world data systems, remains critical to understand how treatments affect outcomes.
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### 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee {#sec3.1.1}
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### From Cynic to Advocate: The Use of Twitter in Cardiology {#sec4.1.1}
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### Social Media in Cardiology: From Optional to Essential {#sec3.1.2}
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### Takotsubo Cardiomyopathy in COVID-19 {#sec5.1.1}
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### QTc Interval Prolongation Is a Proxy for Increased Short-Term Mortality {#sec5.1.2}
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### Healthy Diet and Cardiovascular Prevention: Time to Go Further With a Precision Medicine Approach? {#sec5.1.3}
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### Eat Healthy and Eat More or Less? {#sec5.1.4}
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### Refining Prognostication of Severe Aortic Stenosis: The Q Factor {#sec5.1.6}
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